Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-१.४१%
१,०७६.१३
-१५.३८
-१.४१%
—१,०९१.५११,०९०.४०१,०९०.४०१,०७३.६९——
SIXC
Communications
SIXC
Communications
SIXC
-०.५५%
६०६.७४
-३.३७
-०.५५%
—६१०.११६१०.११६१०.२९६०६.१७——
SIXE
Energy
SIXE
Energy
SIXE
+०.८८%
१,२४८.८२
+१०.८४
+०.८८%
—१,२३७.९८१,२३७.८३१,२५२.४११,२२५.०३——
SIXI
Industrials
SIXI
Industrials
SIXI
-१.१७%
१,७२४.३६
-२०.३५
-१.१७%
—१,७४४.७११,७४०.९५१,७४७.२९१,७२१.५७——
SIXM
Financials
SIXM
Financials
SIXM
-०.७२%
६३५.५९
-४.५९
-०.७२%
—६४०.१८६३९.९२६४३.१९६३४.७३——
SIXR
Staples
SIXR
Staples
SIXR
-०.७६%
८४३.१५
-६.४३
-०.७६%
—८४९.५८८४५.२७८५१.६८८३९.४७——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-०.५५%
२१६.२९
-१.१९
-०.५५%
—२१७.४८२१७.४८२१८.१६२१५.५१——
SIXT
Technology
SIXT
Technology
SIXT
+०.०८%
३,२६३.४१
+२.७२
+०.०८%
—३,२६०.६९३,२७३.३६३,२८७.८१३,२४०.७८——
SIXU
Utilities
SIXU
Utilities
SIXU
-०.३४%
९३९.२४
-३.२१
-०.३४%
—९४२.४५९३९.३९९४८.८०९३३.९८——
SIXV
Health care
SIXV
Health care
SIXV
-०.२९%
१,४६२.५६
-४.२४
-०.२९%
—१,४६६.८०१,४६४.७०१,४६७.१९१,४५८.३६——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-०.७१%
२,३८०.४०
-१७.१०
-०.७१%
—२,३९७.५०२,३९५.०३२,४१२.०१२,३७०.६४——
MVR0:FRA
Medivir AB
€ ०.१४
-१२.६९%
(-०.०२०) 1D
मे ४, २२:००:०० GMT+२  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for MVR0...
Open
€ ०.१४
High
€ ०.१५
Low
€ ०.१४
Mkt. cap
१.०१ अरब
Avg. vol.
२१.००
Volume
०.००
52-wk high
€ ०.२६
52-wk low
€ ०.००
No. of employees
१०
News stories
From sources across the web
Stock Titan
Stock Titan
·
१५ मिनेट पहिले
CRISPR Therapeutics (NASDAQ: CRSP) posts Q1 2026 loss and sells $600M converts
TradingView
TradingView
·
२९ मिनेट पहिले
The Dow Jones Index Closes 1.13% Lower
Seeking Alpha
Seeking Alpha
·
३० मिनेट पहिले
3 things to look out for on Tuesday
AOL.com
AOL.com
·
३२ मिनेट पहिले
S&P 500 to Hit 8,000 This Year? Here's Why JPMorgan Thinks It's Possible
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies. Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides. Medivir is listed on the Nasdaq Stockholm Mid Cap List. In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB
CEOChristine Lind
Employees१०
Founded१९८८
Headquarters-
Sector-
Websitemedivir.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
२०२५ मार्च
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
Revenue
६.०० लाख
१५.०० लाख
१०.०० लाख
५५.०६ लाख
Cost of goods sold
६१.०० लाख
१.७० करोड
८१.०० लाख
१.०२ करोड
Cost of revenue
६१.०० लाख
१.७० करोड
८१.०० लाख
१.०२ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
७०.०० लाख
७१.०० लाख
५८.०० लाख
७१.५५ लाख
Operating expense
८१.०० लाख
७६.०० लाख
६५.०० लाख
३.७७ करोड
Total operating expenses
१.४२ करोड
२.४६ करोड
१.४६ करोड
४.७९ करोड
Operating income
-१.३६ करोड
-२.३१ करोड
-१.३६ करोड
-४.२४ करोड
Other non operating income
२.०० लाख
-
-
-५.०० लाख
EBT including unusual items
-१.३३ करोड
-२.३३ करोड
-१.४६ करोड
-४.३२ करोड
EBT excluding unusual items
-१.३३ करोड
-२.३३ करोड
-१.४६ करोड
-४.३८ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
४.०० लाख
-२.०० लाख
-
-७.०० हजार
Net income
-१.३३ करोड
-२.३३ करोड
-१.४६ करोड
-४.३२ करोड
Net profit margin
-२,२१६.६७%
-१,५५३.३३%
-१,४६०.००%
-७८४.६०%
Earnings per share
-०.१२
-०.२०
-०.१३
-
Interest and investment income
१.०० लाख
-
-
४१.०० हजार
Interest expense
-
-२.०० लाख
-१०.०० लाख
-१३.१२ लाख
Net interest expenses
१.०० लाख
-२.०० लाख
-१०.०० लाख
-१२.७१ लाख
Depreciation and amortization charges
७.०० लाख
७.०० लाख
७.०० लाख
३.०५ करोड
EBITDA
-१.२९ करोड
-२.२४ करोड
-१.२९ करोड
-१.१९ करोड
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer